Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

GLP-1 RA: Glucagon-like peptide-1 (GLP-1 ... [7] Exenatide extended release: A long-acting RA version of exenatide ...

The company’s lead product is a long-acting GLP-1 drug known as MET-097i. In a Phase 1 trial, five weekly injections of the ...

TUESDAY, Nov. 12, 2024 (HealthDay News) — For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...